Stock Research for MNOV

MNOV

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

MNOV Stock Chart & Research Data

The MNOV chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MNOV chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


MNOV Due diligence Resources & Stock Charts

The MNOV stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View MNOV Detailed Price Forecast - CNN Money CNN View MNOV Detailed Summary - Google Finance
Yahoo View MNOV Detailed Summary - Yahoo! Finance Zacks View MNOV Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View MNOV Trends & Analysis - Trade-Ideas Barrons View MNOV Major Holders - Barrons
NASDAQ View MNOV Call Transcripts - NASDAQ Seeking View MNOV Breaking News & Analysis - Seeking Alpha
Spotlight View MNOV Annual Report - CompanySpotlight.com OTC Report View MNOV OTC Short Report - OTCShortReport.com
TradeKing View MNOV Fundamentals - TradeKing Charts View MNOV SEC Filings - Bar Chart
WSJ View Historical Prices for MNOV - The WSJ Morningstar View Performance/Total Return for MNOV - Morningstar
MarketWatch View the Analyst Estimates for MNOV - MarketWatch CNBC View the Earnings History for MNOV - CNBC
StockMarketWatch View the MNOV Earnings - StockMarketWatch MacroAxis View MNOV Buy or Sell Recommendations - MacroAxis
Bullish View the MNOV Bullish Patterns - American Bulls Short Pains View MNOV Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View MNOV Stock Mentions - StockTwits PennyStocks View MNOV Stock Mentions - PennyStockTweets
Twitter View MNOV Stock Mentions - Twitter Invest Hub View MNOV Investment Forum News - Investor Hub
Yahoo View MNOV Stock Mentions - Yahoo! Message Board Seeking Alpha View MNOV Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for MNOV - SECform4.com Insider Cow View Insider Transactions for MNOV - Insider Cow
CNBC View MNOV Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for MNOV - OTC Markets
Yahoo View Insider Transactions for MNOV - Yahoo! Finance NASDAQ View Institutional Holdings for MNOV - NASDAQ


Stock Charts

FinViz View MNOV Stock Insight & Charts - FinViz.com StockCharts View MNOV Investment Charts - StockCharts.com
BarChart View MNOV Stock Overview & Charts - BarChart Trading View View MNOV User Generated Charts - Trading View


Latest Financial News for MNOV

Want To Invest In MediciNova Inc (NASDAQ:MNOV)? Here’s How It Performed Lately
Posted on Wednesday May 16, 2018

After reading MediciNova Inc’s (NASDAQ:MNOV) most recent earnings announcement (31 March 2018), I found it useful to look back at how the company has performed in the past and compareRead More...


MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in Glioblastoma
Posted on Wednesday May 09, 2018

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the Investigational New Drug Application (IND) for MN-166 (ibudilast) for treatment of glioblastoma (GBM) has been accepted and is now open with the U.S. Food and Drug Administration (FDA). MediciNova was informed by the FDA that the proposed clinical investigation of MN-166 (ibudilast) in combination with temozolomide (TMZ) for treatment of GBM may proceed.


MediciNova to Present at the UBS Global Healthcare Conference in New York
Posted on Tuesday May 08, 2018

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that MediciNova will present a corporate overview at the UBS Global Healthcare Conference on Monday, May 21, 2018 at 9:00 am at the Grand Hyatt New York in New York City.  Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through UBS. MediciNova, Inc. is a publicly-traded biopharmaceutical company founded on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with high unmet medical needs with a primary commercial focus on the U.S. market.


MediciNova Announces Plans to Collaborate with UCLA Researchers in Grant-Funded Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder and Withdrawal
Posted on Monday May 07, 2018

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to initiate a clinical trial of MN-166 (ibudilast) in alcohol dependence and withdrawal in collaboration with researchers at the University of California, Los Angeles (UCLA).


Enter a stock symbol to view the stock details.